NEW YORK, Aug. 7 (UPI) -- Former ImClone Systems Chief Executive Officer Samuel Waksal was indicted Wednesday on charges of insider trading, perjury, bank fraud and obstruction of justice. Waksal was accused of tipping off relatives that ImClone's application to market anti-cancer drug Erbitux was going to be rejected by the Food and Drug Administration, before the news became public on Dec. 28.
Advertisement